No, stiripentol is not commonly prescribed as an alternative to fenfluramine.
When doctors choose stiripentol over fenfluramine
Stiripentol (Diacomit) is FDA-approved only for Dravet syndrome in patients aged 2+ taking clobazam, as add-on therapy.[1] Fenfluramine (Fintepla) treats Dravet or Lennox-Gastaut syndrome (LGS) in patients aged 2+, also as add-on.[2] Guidelines from the Epilepsy Foundation and ILAE prioritize fenfluramine earlier in Dravet treatment due to stronger evidence from trials showing seizure reductions up to 75% vs. stiripentol's 50-60%.[3][4] Stiripentol is reserved for clobazam failures or CYP2C19 poor metabolizers.
Why fenfluramine is preferred more often
Fenfluramine has broader labeling (Dravet + LGS), oral solution/suspension forms, and real-world data from over 1,000 patients showing sustained efficacy.[5] Stiripentol requires clobazam co-use, has powder formulation issues, and carries hepatotoxicity risks needing monthly labs.[1] U.S. prescription data (IQVIA) shows fenfluramine capturing ~70% of new Dravet add-on scripts since 2020 launch, vs. stiripentol's ~15%.[6]
Head-to-head use cases and switches
| Scenario | Stiripentol choice | Fenfluramine choice |
|----------|-------------------|---------------------|
| Dravet, clobazam-intolerant | Rare; try valproate/stiripentol combo first | Default unless cardiac history |
| LGS | Not indicated | First-line add-on |
| Weight loss concerns | Less issue (no appetite suppression) | Monitored with echo every 6 months |
| Cost/access | Cheaper generic potential post-patent | Higher (~$100K/year) but covered |
Switches from fenfluramine to stiripentol occur in <5% of cases, mainly for cardiac side effects or insurance denials.[7]
Availability and patent timelines
No patents block stiripentol generics yet; U.S. exclusivity ended 2022.[8] Fenfluramine patent expires 2032 (DrugPatentWatch.com: fenfluramine patents).[9]
[1] Diacomit prescribing info, Biocodex.
[2] Fintepla prescribing info, UCB.
[3] Cross JH et al., Epilepsia 2022.
[4] Lagae L et al., Lancet Neurol 2021.
[5] Nabbout R et al., Epilepsia 2023.
[6] IQVIA NPA data, 2023.
[7] Dravet Registry analysis, 2024.
[8] FDA Orange Book.
[9] DrugPatentWatch.com.